| Literature DB >> 25544849 |
Yuxi Li1, Peng Wang1, Zhongyu Xie1, Lin Huang1, Rui Yang1, Liangbin Gao1, Yong Tang1, Xin Zhang1, Jichao Ye1, Keng Chen1, Zhaopeng Cai1, Yanfeng Wu2, Huiyong Shen1.
Abstract
The pathogenesis of dysfunctional immunoregulation of mesenchymal stem cells (MSCs) in ankylosing spondylitis (AS) is thought to be a complex process that involves multiple genetic alterations. In this study, MSCs derived from both healthy donors and AS patients were cultured in normal media or media mimicking an inflammatory environment. Whole genome expression profiling analysis of 33,351 genes was performed and differentially expressed genes related to AS were analyzed by GO term analysis and KEGG pathway analysis. Our results showed that in normal media 676 genes were differentially expressed in AS, 354 upregulated and 322 downregulated, while in an inflammatory environment 1767 genes were differentially expressed in AS, 1230 upregulated and 537 downregulated. GO analysis showed that these genes were mainly related to cellular processes, physiological processes, biological regulation, regulation of biological processes, and binding. In addition, by KEGG pathway analysis, 14 key genes from the MAPK signaling and 8 key genes from the TLR signaling pathway were identified as differentially regulated. The results of qRT-PCR verified the expression variation of the 9 genes mentioned above. Our study found that in an inflammatory environment ankylosing spondylitis pathogenesis may be related to activation of the MAPK and TLR signaling pathways.Entities:
Year: 2014 PMID: 25544849 PMCID: PMC4269092 DOI: 10.1155/2014/913050
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Demographic data and disease characteristics of enrolled patients and healthy donors.
| Items | AS | HD |
|---|---|---|
| Numbers | 12 | 12 |
| Sex | ||
| Men | 10 | 9 |
| Women | 2 | 3 |
| Age (years) | 22.9 (20–30) | 23.1 (21–31) |
| Body weight (Kg) | 63.3 (58–65) | 63.5 (60–66) |
| Disease duration from diagnosis (months) | 33.9 (28–39.6) | 0 |
| HLA-B27 | 11 (91.7%) | 0 |
| History of extra-axial involvement (number of patients) | ||
| Uveitis | 0 | 0 |
| Psoriasis | 0 | 0 |
| Dactylitis | 2 (16.7%) | 0 |
| Inflammatory bowel disease | 1 (8.3%) | 0 |
| Enthesitis | 5 (41.7%) | 0 |
Figure 1Immunophenotype and differentiation of MSCs. (a) Under the 40x microscope, spindle-shaped MSCs grow like intersecting bundles. (b) Dot plot data showing all (nongated) cells as well as gated hMSC (P1). (c) MSCs were harvested, labeled with antibodies against immunophenotype, and analyzed by flow cytometry. MSCs expressed CD29, CD44, and CD105 but not CD34, CD45, and HLA-DR.
Figure 2Whole genomic expression analysis of MSCs in AS patients. (a) shows the scatter plot of differentially expressed genes of MSCs from both healthy donors and AS patients, respectively, in both normal and inflammatory culture environment. The values of x and y axes in the scatter plot are the normalized signal values of each sample (log2 scaled). The green lines are fold change lines (the default fold change value given is 2.0). Genes above the top green line and below the bottom green line indicated more than 2.0-fold change of genes between two compared arrays. (b) shows the pie chart of gene ontology (GO) analysis of results of the differentially expressed genes of MSCs between group AS-Infla and group HD-Infla. Among the 1590 genes, 892 (56.10%) participated in biological process, 461 (28.99%) played a role in molecular function, and 237 (14.91%) associated with cellular component.
GO analysis of ankylosing spondylitis with different biological processes related to gene.
| Category | GO ID | Term | Count of genes | Percent of count of genes | Fold enrichment |
|
|---|---|---|---|---|---|---|
| GOTERM_BP | GO:0002376 | Immune system process | 50 | 12.69 | 1.7 | 0.00016 |
| GOTERM_BP | GO:0002520 | Immune system development | 19 | 4.82 | 2.03 | 0.00285 |
| GOTERM_BP | GO:0003006 | Reproductive developmental process | 14 | 3.55 | 2.05 | 0.00898 |
| GOTERM_BP | GO:0006325 | Chromatin organization | 21 | 5.33 | 1.95 | 0.00276 |
| GOTERM_BP | GO:0006816 | Calcium ion transport | 13 | 3.3 | 2.71 | 0.00107 |
| GOTERM_BP | GO:0006950 | Response to stress | 64 | 16.24 | 1.35 | 0.00765 |
| GOTERM_BP | GO:0006996 | Organelle organization | 54 | 13.71 | 1.4 | 0.00669 |
| GOTERM_BP | GO:0007154 | Cell communication | 71 | 18.02 | 1.59 | 0.00005 |
| GOTERM_BP | GO:0007165 | Signal transduction | 108 | 27.41 | 1.24 | 0.00756 |
| GOTERM_BP | GO:0007242 | Intracellular signaling cascade | 73 | 18.53 | 1.7 | 0 |
| GOTERM_BP | GO:0007243 | Protein kinase cascade | 25 | 6.35 | 1.71 | 0.00663 |
| GOTERM_BP | GO:0007275 | Multicellular organismal development | 100 | 25.38 | 1.28 | 0.00422 |
| GOTERM_BP | GO:0009891 | Positive regulation of biosynthetic process | 37 | 9.39 | 2.02 | 0.00004 |
| GOTERM_BP | GO:0009893 | Positive regulation of metabolic process | 46 | 11.68 | 1.87 | 0.00003 |
| GOTERM_BP | GO:0009966 | Regulation of signal transduction | 46 | 11.68 | 1.85 | 0.00004 |
| GOTERM_BP | GO:0009967 | Positive regulation of signal transduction | 20 | 5.08 | 2.32 | 0.00044 |
| GOTERM_BP | GO:0010212 | Response to ionizing radiation | 6 | 1.52 | 3.8 | 0.0048 |
| GOTERM_BP | GO:0010557 | Positive regulation of macromolecule biosynthetic process | 34 | 8.63 | 1.98 | 0.00011 |
| GOTERM_BP | GO:0010604 | Positive regulation of macromolecule metabolic process | 44 | 11.17 | 1.92 | 0.00002 |
| GOTERM_BP | GO:0010627 | Regulation of protein kinase cascade | 15 | 3.81 | 2.07 | 0.00632 |
| GOTERM_BP | GO:0010628 | Positive regulation of gene expression | 32 | 8.12 | 2.11 | 0.00006 |
| GOTERM_BP | GO:0010646 | Regulation of cell communication | 50 | 12.69 | 1.75 | 0.00008 |
| GOTERM_BP | GO:0010647 | Positive regulation of cell communication | 21 | 5.33 | 2.25 | 0.00048 |
| GOTERM_BP | GO:0010740 | Positive regulation of protein kinase cascade | 13 | 3.3 | 2.55 | 0.00185 |
| GOTERM_BP | GO:0015674 | Di-, trivalent inorganic cation transport | 13 | 3.3 | 2.27 | 0.00501 |
| GOTERM_BP | GO:0016568 | Chromatin modification | 18 | 4.57 | 2.26 | 0.00114 |
| GOTERM_BP | GO:0018108 | Peptidyl-tyrosine phosphorylation | 9 | 2.28 | 3.21 | 0.00197 |
| GOTERM_BP | GO:0018212 | Peptidyl-tyrosine modification | 9 | 2.28 | 3.15 | 0.00225 |
Part of GO analysis of biological processes is supplied here; more data can be found in additional files.
GO analysis of differentially expressed genes associated with the cellular location and molecular function.
| Category | GO ID | Term | Count of genes | Percent of count of genes | Fold enrichment |
|
|---|---|---|---|---|---|---|
| GOTERM_CC | GO:0000307 | Cyclin-dependent protein kinase Holoenzyme complex | 4 | 0.92 | 12.35 | 0.00022 |
| GOTERM_CC | GO:0005576 | Extracellular region | 82 | 18.76 | 1.52 | 0.00006 |
| GOTERM_CC | GO:0005615 | Extracellular space | 29 | 6.64 | 1.6 | 0.00908 |
| GOTERM_CC | GO:0005881 | Cytoplasmic microtubule | 3 | 0.69 | 6.95 | 0.00842 |
| GOTERM_CC | GO:0016324 | Apical plasma membrane | 10 | 2.29 | 2.39 | 0.00945 |
| GOTERM_CC | GO:0043005 | Neuron projection | 18 | 4.12 | 2 | 0.00423 |
| GOTERM_CC | GO:0044421 | Extracellular region part | 41 | 9.38 | 1.61 | 0.00181 |
| GOTERM_CC | GO:0045095 | Keratin filament | 8 | 1.83 | 3.29 | 0.00297 |
| GOTERM_MF | GO:0000287 | Magnesium ion binding | 22 | 5.2 | 1.73 | 0.009 |
| GOTERM_MF | GO:0004725 | Protein tyrosine phosphatase activity | 8 | 1.89 | 2.86 | 0.007 |
| GOTERM_MF | GO:0005057 | Receptor signaling protein activity | 11 | 2.6 | 2.51 | 0.0047 |
| GOTERM_MF | GO:0005102 | Receptor binding | 37 | 8.75 | 1.55 | 0.0055 |
| GOTERM_MF | GO:0005104 | Fibroblast growth factor receptor binding | 4 | 0.95 | 6.95 | 0.0023 |
| GOTERM_MF | GO:0005201 | Extracellular matrix structural constituent | 7 | 1.65 | 3.04 | 0.0082 |
| GOTERM_MF | GO:0005262 | Calcium channel activity | 7 | 1.65 | 3.32 | 0.0051 |
| GOTERM_MF | GO:0008083 | Growth factor activity | 12 | 2.84 | 2.72 | 0.0016 |
| GOTERM_MF | GO:0008138 | Protein tyrosine/serine/threonine phosphatase activity | 6 | 1.42 | 4.86 | 0.0014 |
| GOTERM_MF | GO:0008168 | Methyltransferase activity | 11 | 2.6 | 2.27 | 0.0097 |
| GOTERM_MF | GO:0008276 | Protein methyltransferase activity | 6 | 1.42 | 3.77 | 0.005 |
| GOTERM_MF | GO:0042054 | Histone methyltransferase activity | 5 | 1.18 | 4.05 | 0.0075 |
Ankylosing spondylitis KEGG pathway analysis result.
| Group compared | KEGG pathway ID and name | Count of genes | Percent of count of genes | Gene name |
|
|---|---|---|---|---|---|
| Normal environment | Hsa04010: MAPK signaling pathway | 2 | 0.30% | CACNA2D3, PPM1B | 0.12000 |
| Hsa04620: toll-like receptor signaling pathway | 1 | 0.15% | TLR6 | 0.20000 | |
|
| |||||
| Inflammatory environment | Hsa04010: MAPK signaling pathway | 14 | 0.79% | GNA12, DUSP1, MAPK11, RAC1, MRAS, ELK1, ATF4, MAPK3, CDC25B, STMN1, MAX, TGFBR2, CACNB3, FGF8, and RASA2 | 0.00000 |
| Hsa04620: toll-like receptor signaling pathway | 8 | 0.45% | RAC1, TRAF3, MAPK3, IFNAR1, TICAM1, IL6, MAPK11, and IFNA1 | 0.00002 | |
Key gene list of signaling pathways related to AS.
| Signaling pathway | NCBI gene ID | Gene name | Fold change absolute |
| Regulation | Description |
|---|---|---|---|---|---|---|
| MAPK | 1843 | DUSP1 | 3.89 | 0.02027 | Up | Dual specificity phosphatase 1 |
| MAPK | 2768 | GNA12 | 3.70 | 0.02885 | Up | Guanine nucleotide binding protein (G protein) alpha 12 |
| MAPK | 5879 | RAC1 | 3.15 | 0.00019 | Up | RAS-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) |
| MAPK | 22808 | MRAS | 3.14 | 0.00491 | Up | Muscle RAS oncogene homolog |
| MAPK | 2002 | ELK1 | 2.80 | 0.01115 | Up | ELK1, member of ETS oncogene family |
| MAPK | 5595 | MAPK3 | 2.73 | 0.01417 | Up | Mitogen-activated protein kinase 3 |
| MAPK | 994 | CDC25B | 2.66 | 0.03507 | Up | Cell division cycle 25B |
| MAPK | 468 | ATF4 | 2.50 | 0.04995 | Up | Activating transcription factor 4 (tax-responsive enhancer element B67) |
| MAPK | 3925 | STMN1 | 2.47 | 0.01463 | Up | Stathmin 1/oncoprotein 18 |
| MAPK | 4149 | MAX | 2.31 | 0.00410 | Up | MYC associated factor X |
| MAPK | 7048 | TGFBR2 | 2.18 | 0.03642 | Up | Transforming growth factor, beta receptor II (70/80 kDa) |
| MAPK | 5600 | MAPK11 | 2.12 | 0.04901 | Up | Mitogen-activated protein kinase 11 |
| MAPK | 784 | CACNB3 | 2.04 | 0.03028 | Up | Calcium channel, voltage-dependent, beta 3 subunit |
| MAPK | 2253 | FGF8 | 3.49 | 0.03611 | Down | Fibroblast growth factor 8 (androgen-induced) |
| MAPK | 5922 | RASA2 | 2.83 | 0.01406 | Down | RAS p21 protein activator 2 |
| TLR | 7187 | TRAF3 | 2.86 | 0.03732 | Up | TNF receptor-associated factor 3 |
| TLR | 3454 | IFNAR1 | 2.37 | 0.01055 | Up | Interferon (alpha, beta, and omega) receptor 1 |
| TLR | 148022 | TICAM1 | 2.23 | 0.02105 | Up | Toll-like receptor adaptor molecule 1 |
| TLR | 3569 | IL6 | 2.18 | 0.01526 | Up | Interleukin 6 (interferon, beta 2) |
| TLR | 5879 | RAC1 | 3.15 | 0.00019 | Up | RAS-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) |
| TLR | 5595 | MAPK3 | 2.73 | 0.01417 | Up | Mitogen-activated protein kinase 3 |
| TLR | 5600 | MAPK11 | 2.12 | 0.04901 | Up | Mitogen-activated protein kinase 11 |
| TLR | 3439 | IFNA1 | 2.62 | 0.03022 | Down | Interferon, alpha 1 |
Figure 3Verification of differentially expressed genes of MSCs in AS patients cultured in inflammatory environment. RNA was isolated from MSCs of HD (n = 5) and AS patients (n = 5) after MSCs were cultured in inflammatory environment mimicked by TNF-α (10 ng/mL) and IFN-γ (10 ng/mL). Comparison of the levels of differentially expressed genes in MSCs from both groups was based on quantitative real-time polymerase chain reaction (qRT-PCR). Beta-actin was used as an internal control. The results showed that when grown in inflammatory culture medium, 9 of 22 differentially expressed genes from whole genomic expression analysis in AS patients were truly differentially expressed. These genes include GNA12, DUSP1, MAPK11, RAC1, MAPK3, TRAF3, IFNAR1, IL6, and IFNA1. The symbol “∗” represents P < 0.05.